Ann & Robert H Lurie Children's Hospital of Chicago
This goal of this study is to assess the safety and immunogenicity of recombinant zoster virus in young adult solid organ transplant recipients. In this study, participants will receive the recombinant zoster vaccine. They will be monitored for adverse events and tested for antibody and cellular immunity.
This is an open-label, non-blinded study to assess the safety and immunogenicity of the Recombinant Zoster Vaccine (RZV) in young adult recipients of solid organ transplants (heart, liver, kidney). After obtaining consent, the patient will have pre-vaccine baseline Varicella Zoster Virus (VZV) anti-gE antibody testing performed by the Weinberg lab and then will be given first dose of vaccine. Participants will be brought back 30-60 days post-vaccine for follow up testing and second dose of vaccine. Participants will then be brought in for follow-up testing at 1-2 months, 6 months, and 12-15 mo…
Inclusion Criteria: * 19 years of age or older and willing to provide written informed consent for the study participation. * Prior recipient of solid organ transplant more than one year prior to participation. * Stable immunosuppressive medication regimen for last 6 months prior to participation * Participant must have a working telephone number, email address or patient Electronic Health Record (EHR) portal access and be willing to be contacted for study follow-up by any of these means. * For participants of childbearing potential, use of effective pregnancy prevention till 2 months post la…
After giving consent, participants will be given first dose of vaccine. Participants will be brought back 60-90 days post-vaccine for follow up testing and second dose of vaccine
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.